PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Flaifel, Abdallah; Xie, Wanling; Braun, David A; Ficial, Miriam; Bakouny, Ziad; Nassar, Amin H; Jennings, Rebecca B; Escudier, Bernard; George, Daniel J; Motzer, Robert J; Morris, Michael J; Powles, Thomas; Wang, Evelyn; Huang, Ying; Freeman, Gordon J; Choueiri, Toni K; Signoretti, Sabina.
Clin Cancer Res; 2019 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-31371341

Não foram localizados documentos relacionados